{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T05:19:15Z","timestamp":1782191955244,"version":"3.54.5"},"reference-count":10,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejinme.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Internal Medicine"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1016\/j.ejim.2023.05.011","type":"journal-article","created":{"date-parts":[[2023,5,12]],"date-time":"2023-05-12T01:04:24Z","timestamp":1683853464000},"page":"143-145","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Therapeutic challenges and cardiovascular risk in patients with HMGCR-associated immune-mediated necrotizing myopathy (HMGR-IMNM) secondary to statins"],"prefix":"10.1016","volume":"114","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1108-9461","authenticated-orcid":false,"given":"Jorge","family":"\u00c1lvarez-Troncoso","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio Carrasco","family":"Molina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1ngel","family":"Robles-Marhuenda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Mart\u00ednez-Robles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Jos\u00e9","family":"R\u00edos-Blanco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.ejim.2023.05.011_bib0001","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s11926-018-0732-6","article-title":"Immune-mediated necrotizing myopathy","volume":"20","author":"Pinal-Fernandez","year":"2018","journal-title":"Curr Rheumatol Rep"},{"issue":"3","key":"10.1016\/j.ejim.2023.05.011_bib0002","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1097\/MD.0000000000000028","article-title":"Anti-HMGCR autoantibodies in european patients with autoimmune necrotizing myopathies","volume":"93","author":"Allenbach","year":"2014","journal-title":"Medicine (Baltimore)"},{"issue":"3","key":"10.1016\/j.ejim.2023.05.011_bib0003","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1002\/art.30156","article-title":"Autoantibodies against 3-hydroxy-3-methylglutaryl-coenzyme A reductase in patients with statin-associated autoimmune myopathy","volume":"63","author":"Mammen","year":"2011","journal-title":"Arthritis & Rheum"},{"issue":"17","key":"10.1016\/j.ejim.2023.05.011_bib0004","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1056\/NEJMc1506163","article-title":"Intravenous immune globulin for statin-triggered autoimmune myopathy","volume":"373","author":"Mammen","year":"2015","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.ejim.2023.05.011_bib0005","doi-asserted-by":"crossref","first-page":"623","DOI":"10.3899\/jrheum.171495","article-title":"Rituximab in the treatment of refractory anti-HMGCR immune-mediated necrotizing myopathy","volume":"46","author":"Landon-Cardinal","year":"2018","journal-title":"J Rheumatol"},{"issue":"10","key":"10.1016\/j.ejim.2023.05.011_bib0006","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1007\/s11926-020-00942-3","article-title":"Lipid-lowering therapies in myositis","volume":"22","author":"Mizus","year":"2020","journal-title":"Curr Rheumatol Rep"},{"issue":"11","key":"10.1016\/j.ejim.2023.05.011_bib0007","first-page":"e596","article-title":"ACC\/AHA guideline on the primary prevention of cardiovascular disease: a report of the American college of cardiology\/American heart association task force on clinical practice guidelines","volume":"140","author":"Arnett","year":"2019","journal-title":"Circulation"},{"issue":"34","key":"10.1016\/j.ejim.2023.05.011_bib0008","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1093\/eurheartj\/ehab484","article-title":"ESC guidelines on cardiovascular disease prevention in clinical practice","volume":"42","author":"Visseren","year":"2021","journal-title":"Eur Heart J"},{"issue":"1","key":"10.1016\/j.ejim.2023.05.011_bib0009","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"41","author":"Mach","year":"2019","journal-title":"Eur Heart J"},{"issue":"11","key":"10.1016\/j.ejim.2023.05.011_bib0010","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1056\/NEJMoa1803917","article-title":"Safety and efficacy of bempedoic acid to reduce LDL cholesterol","volume":"380","author":"Ray","year":"2019","journal-title":"N Engl J Med"}],"container-title":["European Journal of Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620523001656?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620523001656?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T09:38:39Z","timestamp":1760607519000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0953620523001656"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":10,"alternative-id":["S0953620523001656"],"URL":"https:\/\/doi.org\/10.1016\/j.ejim.2023.05.011","relation":{},"ISSN":["0953-6205"],"issn-type":[{"value":"0953-6205","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Therapeutic challenges and cardiovascular risk in patients with HMGCR-associated immune-mediated necrotizing myopathy (HMGR-IMNM) secondary to statins","name":"articletitle","label":"Article Title"},{"value":"European Journal of Internal Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejim.2023.05.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}